RxDoctor Payments Data

Ruth Bochat

Family · Port Jefferson Station, NYNPI 1124618228

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,302 of the $22,615 with a category attached, or 67.7%. 33 manufacturers reported payments, led by Boston Scientific at 28.2% of the total. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,615in general payments, 2019–2025

Across 318 payments — averaging $71.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • MML US, Inc.$5K
  • Relievant Medsystems, Inc.$3K
  • Saluda Medical Americas, Inc.$2K
  • Nalu Medical, Inc.$2K
  • Foundation Fusion Solutions, LLC$1K
  • plus $4K from 27 others

What the payments were for

  • Consulting fees$6903%
  • Speaking & faculty fees$900%
  • Travel & lodging$6,50029%
  • Food & beverage$15,30268%
  • Entertainment$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,615 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$9,478
Medicare patients
52
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$9,263
MovantikNaloxegol Oxalate19$7,762
Oxycodone Hcl52$1,162
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen42$1,098
Gabapentin77$785
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen51$772
Pregabalin27$683
Tramadol Hcl48$648
Baclofen26$522
Tizanidine Hcl20$127
Cyclobenzaprine Hcl27$97
Methylprednisolone11$86
Meloxicam21$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$103$9,26317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →